Heidi W. Moore
Heidi W. Moore is a NYC-based writer and editor of multimedia, digital, and print content for professional and consumer audiences. Her portfolio includes health, wellness, and medical topics with occasional forays into fashion and finance.
Is Blue Light Causing Skin Damage?
Angela Casey, MD, relates her experiences addressing patients’ concerns about skin damage caused by blue light.
Treating Teenage Acne
Tiffany Link, MD, PhD, reviews some strategies for addressing the specific needs and constraints of treating teenage patients with acne.
Dermatologist Inaugurated as AMA President
Jack S. Resneck Jr., MD, was inaugurated as the 177th president of the American Medical Association (AMA). He is a dermatologist, professor, and vice-chair of the Department of Dermatology at UC San Francisco.
Acne Awareness Month 2022—Practice Insights
For this year’s Acne Awareness Month, Savina Aneja, MD, talks with us about what she’s currently seeing in her practice–with treatment that now ranges from traditional to high tech.
Skin Cancer Awareness Month: Protection Is Prevention
Patient awareness of sun damage doesn’t always translate into safer sun practices, finds Lisa Nyanda-Manola, MD. She describes how she counsels her patients, especially those with skin of color, to protect themselves.
Aesthetic Procedures: Support for Patients and Partners
Esther Yoonah Kim, MD and her colleague, Andy Wongworawat, MD, discuss patient “support” as it encompasses emotional, physical, and financial aspects of care.
A Self-Funded Dermatology Residency Program: ADCS
We speak with Charles Dunn, MD, about his experiences in a unique dermatology residency program offered by a nationwide clinic, Advanced Dermatology and Cosmetic Surgery.
What to Expect at the 2022 American Academy of Dermatology Annual Meeting
The team at Dermatology Advisor will be reporting on the latest news and research conducted by leading experts in dermatology and presented at the 2022 American Academy of Dermatology Annual Meeting, being held live from March 25 through March 29 in Boston, Massachusetts.
Empowering the Digital Patient
Margareth Pierre-Louis, MD, MBA, spoke with us about patients’ expectations of convenient, on-demand care and how it will determine who survives in the digital health care environment.
Vitiligo: Present and Future, With John E. Harris, MD
Expert on vitiligo John E. Harris, MD, associate professor of dermatology at University of Massachusetts Medical School (UMMS) in Worcester, spoke with us about the skin disorder.
Update: Facial Filler Use Now Reported by Moderna COVID-19 Vaccine Trial Participants
Moderna mRNA-1273-P301 study participants will now be asked to disclose information about their use of facial fillers.
Facial Fillers and the COVID-19 Vaccine
The American Society for Dermatologic Surgery (ASDS) has released a new guidance regarding adverse events associated with the SARS-CoV-2 mRNA vaccine and dermal fillers.
Anifrolumab May Reduce Skin Disease Severity in Patients With Active Systemic Lupus Erythematosus
Researchers evaluated the effect on skin-specific systemic lupus erythematosus disease activity using data pooled from the TULIP-1 and TULIP-2 trials.
Is It COVID-19 or Is It Your Meds?
Taste and smell disturbances are common symptoms of COVID-19, but they can also be caused by medications frequently prescribed by dermatologists.
Do TNFis Reduce the Risk for Progression to PsA in Patients With Psoriasis?
Researchers evaluated the use of TNFis vs methotrexate in reducing the risk for progression to psoriatic arthritis in patients with psoriasis.
COVID Toes: Dermatologic Observations and Theories
Observations and theories about the emergence of “COVID toes” in patients are discussed with Adam Friedman, MD, FAAD.
Registries Established for Patients With Psoriasis, Atopic Dermatitis, and COVID-19
New registries have been established to capture emerging data on patients with psoriasis and atopic dermatitis who have COVID-19.
Biologic, Immunosuppressive Therapies Not Tied to Severe Outcomes From COVID-19 Infection
A study from Italy reports severe outcomes related to the COVID-19 infection in patients with chronic plaque psoriasis receiving immunosuppressive therapies.
Managing Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa During COVID-19
The outbreak of COVID-19 affects the management of chronic dermatologic disease in those patients already receiving therapy and patients about to begin a new treatment.
Management of Systemic Immunomodulators During the COVID-19 Pandemic
An understanding of pathophysiology may serve to guide clinical decision making when using biologic agents during the COVID-19 pandemic.